Cargando…

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

INTRODUCTION: Individual variability of rivaroxaban was observed in clinical application. This study aimed to identify genetic variants associated with the variability of pharmacodynamics and bleeding risk of rivaroxbaban in patients with nonvalvular atrial fibrillation (NVAF). MATERIALS AND METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Qian, Wang, Zhe, Mu, Guangyan, Xie, Qiufen, Liu, Zhiyan, Zhou, Shuang, Zhang, Hanxu, Wang, Zining, Jiang, Jie, Hu, Kun, Zhang, Yatong, Zhao, Zinan, Yuan, Dongdong, Guo, Liping, Wu, Tingting, Zhang, Jinhua, Wang, Na, Xiang, Jing, Gu, Zhichun, Sun, Jianjun, Cui, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196221/ https://www.ncbi.nlm.nih.gov/pubmed/37203300 http://dx.doi.org/10.1002/ctm2.1263

Ejemplares similares

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study
por: Xiang, Qian, et al.
Publicado: (2022)

Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic–pharmacodynamic profiles of rivaroxaban
por: Zhang, Hanxu, et al.
Publicado: (2022)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
por: Zhao, Nan, et al.
Publicado: (2022)

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population
por: Zhang, Fan, et al.
Publicado: (2022)

Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
por: Liu, Zhiyan, et al.
Publicado: (2022)

SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population
por: Xie, Qiufen, et al.
Publicado: (2022)

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report
por: Xiang, Qian, et al.
Publicado: (2020)

Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis
por: Xie, Qiufen, et al.
Publicado: (2022)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Association between smokeless tobacco use and oral cavity cancer risk in women compared with men: a systematic review and meta-analysis
por: Mu, Guangyan, et al.
Publicado: (2021)

Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation
por: Zhao, Mindi, et al.
Publicado: (2022)

Effectiveness and Safety of Platelet ADP–P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta‐Analysis
por: Liu, Zhiyan, et al.
Publicado: (2019)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
por: Tamayo, Sally, et al.
Publicado: (2015)

Ferroptosis of Endothelial Cells in Vascular Diseases
por: Zhang, Hanxu, et al.
Publicado: (2022)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Efficacy and Safety of Novel Oral P2Y(12) Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis
por: Sun, Jianjun, et al.
Publicado: (2017)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
por: Ahrens, Ingo, et al.
Publicado: (2014)

Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
por: Kitazono, Takanari, et al.
Publicado: (2019)

Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation
por: Koge, Junpei, et al.
Publicado: (2022)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Ngo, Lien Thi, et al.
Publicado: (2020)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
por: Li, Xin, et al.
Publicado: (2020)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
por: Alberts, Mark J., et al.
Publicado: (2022)

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation
por: Wu, Tingting, et al.
Publicado: (2023)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
por: Liu, Xiao-Qin, et al.
Publicado: (2023)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation
por: Chiou, Wei-Ru, et al.
Publicado: (2023)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies
por: Wang, Yimin Pearl, et al.
Publicado: (2020)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f15sfeuf7ek20jr8fesjork7o9